International Assets Investment Management LLC Makes New $7.04 Million Investment in Sanofi (NASDAQ:SNY)

International Assets Investment Management LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 122,118 shares of the company's stock, valued at approximately $7,038,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Barrow Hanley Mewhinney & Strauss LLC raised its position in Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company's stock valued at $288,381,000 after buying an additional 3,164,092 shares during the period. Magnetar Financial LLC increased its holdings in shares of Sanofi by 1,153.1% in the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company's stock valued at $121,605,000 after purchasing an additional 2,306,286 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company's stock worth $417,017,000 after purchasing an additional 1,370,232 shares in the last quarter. Mondrian Investment Partners LTD boosted its holdings in shares of Sanofi by 43.1% during the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company's stock worth $192,023,000 after purchasing an additional 1,190,141 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in Sanofi by 3,440.6% in the 1st quarter. BNP Paribas Financial Markets now owns 1,033,549 shares of the company's stock valued at $50,230,000 after buying an additional 1,004,358 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of research reports. Citigroup raised shares of Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. StockNews.com upgraded Sanofi from a "buy" rating to a "strong-buy" rating in a report on Wednesday. Finally, Argus lifted their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, July 26th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of "Buy" and a consensus target price of $57.50.

Sanofi Stock Performance

Shares of SNY stock traded up $0.55 during trading on Friday, reaching $53.43. The company had a trading volume of 199,898 shares, compared to its average volume of 2,030,414. The company has a market capitalization of $135.60 billion, a PE ratio of 26.98, a PEG ratio of 1.36 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm's 50 day simple moving average is $55.98 and its two-hundred day simple moving average is $51.91. Sanofi has a one year low of $45.00 and a one year high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analysts' expectations of $16.59 billion. During the same period in the previous year, the company earned $2.55 earnings per share. Sanofi's revenue for the quarter was up 12.3% on a year-over-year basis. Sell-side analysts forecast that Sanofi will post 4.27 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.